Is ibogaine treatment durable? 12-month follow-up of magnesium-ibogaine therapy (MISTIC) in Special Operations Veterans with traumatic brain injuries

Faerman, Afik, Lissemore, Jennifer I., Geoly, Andrew D., Cherian, Kirsten N., Sridhar, Malvika, Kim, Bora, Coetzee, John P., Anker, Lauren, Shamma, Ahmed, Keynan, Jackob N., Brown, Randi E., Phillips, Angela, Jester, Ashley, Bassano, Nicholas J., Keller, Jennifer, Espil, Flint M., Kratter, Ian H., Rolle, Camarin E., Williams, Nolan R. · 2025 · Preprint

AI-extracted · unverified · confirm at source

12-month follow-up of MISTIC trial (n=25). Sustained large effect sizes (d>0.8) for disability, PTSD, depression, anxiety. 84% PTSD remission at 12 months.

Dosing: 2–3 mg/kg test dose, total <14 mg/kg oral ibogaine HCl (oral)

Sample size: 25

Safety data present: ELECTROLYTE

Contraindications: History of neurological disorders (except TBI), Psychotic symptoms or disorders, Risk for suicidal behaviour, Cardiovascular problems, Liver or kidney problems, Pregnancy, Clinical abnormalities on screening physical exam